past deal critic futur growth
deceler
close versu thursday follow releas
result guidanc sale guidanc in-lin expect
consist manag prior commentari though oper margin
lower street view stori larg unchang
legaci busi growth remain modest estimate deceler year year
urolift vsi provid growth rate remain equal weight
result continu show urolift vsi what drive growth legaci
growth remain modest constant currenc sale growth
includ benefit sell day increment sale neotract
urolift contribut vascular solut vsi ad
includ benefit go-direct convers thu estim legaci teleflex
grew adjust exit surgic product line
deceler level also adjust ship day
success past critic outlook long rang plan
sale growth goal assum base busi contribut
neotract vsi ad given recent perform
base seem outlook increasingli depend urolift vsi well
recent deal essenti medic manta vascular closur devic
manag comment remain activ assess potenti target
despit increas concern around perform legaci busi
increas pt reflect higher ep outlook also increas
target pe ep believ achiev
lrp may bit back-end load
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
continu grow modestli deceler
success past deal notabl
neotract urolift vsi help acceler
overal growth believ sale growth
achiev warrant premium pe
stock current reflect equal weight
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
view result mix headlin number suggest
sale slightli street organ sale growth much
growth come urolift vsi legaci growth ep beat
function lower tax rate oper margins/incom expect
guidanc larg bracket street weight back-half
overal view chang outlook heavili depend continu
success past transact
million except per share data chang sale constant currenc organ basi unless otherwis note
addit detail quarter
addit takeaway confer call
pleas see note click kstew call note
modest clear focu urolift date
urolift strength continu sale
contribut overal growth y/i full year
clinic result continu posit
vascular solut vsi sale increas y/i reflect strong
growth north america emea benefit distributor convers
management announc anoth restructur program expect plan-rel save
begin reach annual pre-tax save plan fulli
implement action expect substanti complet
organ sale growth net ship day quarter increment
urolift sale contribut increment vsi sale contribut
thu base busi grew around exclud surgic exit
ep beat estim sale ahead oper margin came
lower vs estimate result lower oper profit dollar
quarter delta estim beat function lower tax
rate benefit rel estim lower interest expens
mid-pt commentari impli street impli sale
vs street ep vs street
sale report constant currenc organ
basi result benefit addit sell day ad
gross margin y/i reflect effici higher urolift
intervent access sale volum benefit distributor buy-in fx
sg sale y/i
 sale bp y/i
oper margin y/i reflect increas gross
margin offset effect sg
adjust tax rate vs prior year expect
adjust ep street estimate estimate
manag expect report revenu base full year revenu growth guidanc impli
revenu ep expect full year impli quarter manag anticip major
full year fx headwind occur bulk
expect report sale growth constant currenc sale growth guidanc compani project
gross margin expans oper margin expans interest expens tax rate
rang net/net result expect ep bracket street pre-result
abbrevi incom statement million except per share data
incom statementnet inc ex interest inc nc incom barclay
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
